Drug Type Nanobody, Antibody drug conjugate (ADC) |
Synonyms JSKN003/Envafolimab + [1] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC38H43N9O8 |
InChIKeyQODRVHFOPFCZOM-IUDBTDONSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Solid Tumors | Phase 2 | AU | 26 Mar 2024 | |
Solid tumor | Phase 2 | AU | 18 Jan 2024 |
Phase 1/2 | 10 | (yfaczclgpl) = The most common was mild to moderate injection site reactions (Grade 1–2). ikdccsgucx (awwpusowcj ) View more | Positive | 05 Nov 2024 |